Impax Pharmaceuticals Reports Positive Results Of Phase II Trial Of IPX066, A Novel Formulation Of Carbidopa-Levodopa For Parkinson's Disease
Links shared publicly online about this topic.
- 1,728total visits
Impax Pharmaceuticals Reports Positive Results Of Phase II Trial Of IPX066, A Novel Formulation Of Carbidopa-Levodopa For Parkinson's Disease
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) reported the positive results from a recently completed Phase II trial of its late-stage Parkinson's D
View full resource at medicalnewstoday.com
Tags: Parkinson's Disease, Disease and Condition, Pharma
Most Recently Shared on September 23, 2009 at 12:17 pm By:
Impax Pharmaceuticals Reports Positive Results Of Phase II Trial Of IPX066, A Novel Formulation Of Carbidopa-Lev.. http://bit.ly/lEn8x
Advertisement
